VitaPCR™ Influenza A&B/SARS-CoV-2 assay Receives CE Mark
Credo Diagnostics Biomedical Pte. Ltd., the leader of point-of-care rapid molecular diagnostic, announced today it has received CE-Mark for the VitaPCR™ Influenza A&B/SARS-CoV-2 assay, a rapid molecular diagnostic test for qualitative detection of the viruses causing COVID-19, Flu A, and Flu B infections from a single patient sample. The three-in-one test is designed for use […]
